Ginkgo Bioworks (DNA) Stock Price, News & Analysis

Company Overview

Ginkgo Bioworks Holdings Inc. is a biotech company attempting to revolutionize the biotechnology industry by engineering completely new organisms. Founded in 2008 by Jason Kelly, Austin Che, Thomas Knight Jr. and Bartholomew Canton, the company operates a market-agnostic platform utilizing the latest technologies to pioneer the development of more sustainable biotechnology and bioengineering applications. 

Ginkgo Bioworks Holdings Inc. develops multiple platforms for food production, agriculture, industrial and pharmaceuticals. These platforms enable bioengineering applications across diverse markets, and the company customizes organisms for customers ranging from large companies to smaller startups. The company also creates proprietary software, algorithms and automation to engineer "customizable organisms" for their customers and the development of new products for the industrial and consumer markets. 

The company has earned multiple awards for its innovative technology in biologics, including the National Science Foundation's Innovation Corps Award, the National Academy of Engineering's Grand Challenges Award and the World Economic Forum's Technology Pioneers Award. 

Ginkgo Bioworks Holdings Inc. has partnered with prestigious organizations, including the Broad Institute of MIT, Harvard, Genomics England, the National Institutes of Health and the National Science Foundation's Innovation Corps to further their mission of making biotechnology more accessible to smaller and medium-sized organizations. 

Ginkgo Bioworks Holdings Inc. strives to revolutionize the biotech industry, attempting to pioneer the development of an ecosystem that will provide more sustainable and accessible biotechnology systems. With the help of innovative technology and strategic partnerships with prestigious organizations, Ginkgo Bioworks Holdings Inc. is well on its way to achieving this goal and making biotechnology more accessible to smaller and medium-sized organizations.

Ginkgo Bioworks Holdings Inc. has a market cap of approximately $2.97 billion, down from $3.98 in 2022. However, the company has seen rapid growth since 2020, increasing revenues from $3.8 million in 2017 to $313.8 million in 2022. 

Written by Jeffrey Neal Johnson

Key Stats

• Today's Range: $9.49 to $10.37
• 50-Day Range: $6.33 to $11.66
• 52-Week Range: $5.26 to $72.00
• Volume: 773,603 shs
• Average Volume: 1.17 million shs
• Market Capitalization: $555.25 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.58
• Consensus Rating: Reduce

Ginkgo Bioworks Stock Analysis - MarketRank™

Ginkgo Bioworks scored higher than 18% of companies evaluated by MarketBeat, and ranked 875th out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.8 / 5
• Analyst Rating: Reduce

Consensus Rating

Ginkgo Bioworks has received a consensus rating of Reduce. The company's average rating score is 1.60, and is based on 1 buy rating, 1 hold rating, and 3 sell ratings.

Amount of Analyst Coverage

Ginkgo Bioworks has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Ginkgo Bioworks are expected to grow in the coming year, from ($10.02) to ($6.15) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Ginkgo Bioworks is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Ginkgo Bioworks is -0.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Ginkgo Bioworks has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

19.65% of the float of Ginkgo Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Ginkgo Bioworks has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Ginkgo Bioworks has recently decreased by 3.37%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Ginkgo Bioworks does not currently pay a dividend.

Dividend Growth

Ginkgo Bioworks does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

19.65% of the float of Ginkgo Bioworks has been sold short.

Short Interest Ratio / Days to Cover

Ginkgo Bioworks has a short interest ratio ("days to cover") of 6.1.

Change versus previous month

Short interest in Ginkgo Bioworks has recently decreased by 3.37%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 0.96

News Sentiment

Ginkgo Bioworks has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Ginkgo Bioworks this week, compared to 7 articles on an average week.

Search Interest

Only 10 people have searched for DNA on MarketBeat in the last 30 days. This is a decrease of -9% compared to the previous 30 days.

MarketBeat Follows

6 people have added Ginkgo Bioworks to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Ginkgo Bioworks insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,736.00 in company stock.

Percentage Held by Insiders

Only 9.72% of the stock of Ginkgo Bioworks is held by insiders.

Percentage Held by Institutions

78.63% of the stock of Ginkgo Bioworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

DNA Stock Analysis - Frequently Asked Questions

How have DNA shares performed this year?

Ginkgo Bioworks' stock was trading at $8.2950 at the start of the year. Since then, DNA shares have increased by 16.5% and is now trading at $9.66.
View the best growth stocks for 2024 here.

How were Ginkgo Bioworks' earnings last quarter?

Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.08) EPS for the quarter, hitting the consensus estimate of ($0.08). The company had revenue of $37.94 million for the quarter, compared to analyst estimates of $45.50 million. Ginkgo Bioworks had a negative net margin of 298.78% and a negative trailing twelve-month return on equity of 58.54%.

Who are Ginkgo Bioworks' major shareholders?

Ginkgo Bioworks' top institutional shareholders include Baillie Gifford & Co. (6.04%), Anchorage Capital Group L.L.C. (3.14%), Erste Asset Management GmbH (0.90%) and Geode Capital Management LLC (0.75%). Insiders that own company stock include Reshma P Shetty, Barry Canton, Marijn E Dekkers, Jason R Kelly, Christian O Henry, Mark E Dmytruk, Harry Sloan, Marie E Fallon and Steven P Coen.
View institutional ownership trends.

How do I buy shares of Ginkgo Bioworks?

Shares of DNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of Ginkgo Bioworks own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Ginkgo Bioworks investors own include Enovix (ENVX), Symbotic (SYM), JPMorgan Nasdaq Equity Premium Income ETF (JEPQ), COMPASS Pathways (CMPS), Rambus (RMBS), Toast (TOST) and Globant (GLOB).

Company Calendar

• Last Earnings: 5/09/2024
• Today: 12/29/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:DNA
• CUSIP: N/A
• CIK: 1830214
• Web: www.eagleequityptnrs.com
• Phone: 877-442-5362
• Fax: N/A
• Employees: 1,218
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.58
• High Stock Price Target: $10.00
• Low Stock Price Target: $0.30
• Potential Upside/Downside: -52.6%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.60
• Research Coverage: 5 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($13.08)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-892,870,000.00
• Net Margins: -298.78%
• Pretax Margin: -298.94%
• Return on Equity: -58.54%
• Return on Assets: -34.24%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 5.79
• Quick Ratio: 5.79

Sales & Book Value

• Annual Sales: $217.11 million
• Price / Sales: 2.56
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $21.93 per share
• Price / Book: 0.44

Miscellaneous

• Outstanding Shares: 57,479,000
• Free Float: 51,892,000
• Market Cap: $555.25 million
• Optionable: Optionable
• Beta: 1.17